Literature DB >> 23152459

Omega-3 for patients with cardiovascular disease.

Ricky Turgeon1, Fred Janke, Michael R Kolber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23152459      PMCID： PMC3498015     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  15 in total

1.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.

Authors:  Penny M Kris-Etherton; William S Harris; Lawrence J Appel
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

2.  n-3 fatty acids and cardiovascular events after myocardial infarction.

Authors:  Daan Kromhout; Erik J Giltay; Johanna M Geleijnse
Journal:  N Engl J Med       Date:  2010-08-28       Impact factor: 91.245

Review 3.  Fish consumption, fish oil, lipids, and coronary heart disease.

Authors:  N J Stone
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

4.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

Authors: 
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

Review 5.  Omega 3 fatty acids for prevention and treatment of cardiovascular disease.

Authors:  L Hooper; R L Thompson; R A Harrison; C D Summerbell; H Moore; H V Worthington; P N Durrington; A R Ness; N E Capps; G Davey Smith; R A Riemersma; S B J Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 6.  Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Authors:  Sang Mi Kwak; Seung-Kwon Myung; Young Jae Lee; Hong Gwan Seo
Journal:  Arch Intern Med       Date:  2012-05-14

7.  OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

Authors:  Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

8.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Authors:  Mitsuhiro Yokoyama; Hideki Origasa; Masunori Matsuzaki; Yuji Matsuzawa; Yasushi Saito; Yuichi Ishikawa; Shinichi Oikawa; Jun Sasaki; Hitoshi Hishida; Hiroshige Itakura; Toru Kita; Akira Kitabatake; Noriaki Nakaya; Toshiie Sakata; Kazuyuki Shimada; Kunio Shirato
Journal:  Lancet       Date:  2007-03-31       Impact factor: 79.321

9.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Authors:  Luigi Tavazzi; Aldo P Maggioni; Roberto Marchioli; Simona Barlera; Maria Grazia Franzosi; Roberto Latini; Donata Lucci; Gian Luigi Nicolosi; Maurizio Porcu; Gianni Tognoni
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

Authors:  Pilar Galan; Emmanuelle Kesse-Guyot; Sébastien Czernichow; Serge Briancon; Jacques Blacher; Serge Hercberg
Journal:  BMJ       Date:  2010-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.